Pharvaris N.V. Ordinary Shares PHVS

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

• GlobeNewswire Inc. 5 oct

  Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

  Pharvaris-funded analysis of real-world HAE management reveals significant gaps between guideline-recommended care and clinical practice. Study of 225 physicians and 279 patients identified key barriers to treatment adherence, including treatment burden, route of administration, and patient perception of attack severity. Findings highlight unmet needs and suggest oral daily treatment is preferred over injectable options, supporting Pharvaris' development of oral bradykinin B2 receptor antagonists.

  

• GlobeNewswire Inc. 6 ago

  Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

  Pharvaris announced publication of a qualitative study assessing disease burden in AAE-C1INH patients and validating patient-reported outcome measures. The study findings informed the design of the ongoing Phase 3 CREAATE trial investigating deucrictibant for prophylaxis and on-demand treatment of AAE-C1INH attacks. Results demonstrated significant multifaceted disease burden with frequent painful attacks disrupting daily life, and validated the use of established PRO instruments for measuring treatment benefits.

  

• The Motley Fool 24 jul

  After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?

  Pharvaris director Johannes Schikan sold 37,600 shares worth $1.3 million in late June 2026, representing 10.66% of his direct holdings. The sale occurred under a Rule 10b5-1 trading plan following a 96.5% one-year stock price appreciation. Shortly after, the FDA accepted the company's New Drug Application for its lead drug deucrictibant for hereditary angioedema treatment, though the stock has remained relatively flat since the announcement.